NCT05224856View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

January 31, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

CT-P63 and CT-P66 / Placebo

Inhalation

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT05224856 - To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen | Biotech Hunter | Biotech Hunter